Pfizer clinches deal amid bidding war
Pfizer has won the bidding war for Metsera, securing the deal at around $10 billion, after its rival Novo Nordisk exited the contest.
Metsera accepted Pfizer’s improved offer late on Friday, citing higher regulatory and antitrust risks associated with Novo Nordisk’s bid.
The acquisition is seen as a strategic move by Pfizer to establish a foothold in the growing obesity-treatment market, despite Metsera’s therapies still being years away from commercial launch.
Details of the agreement
- Pfizer will pay US $86.25 per share for Metsera, consisting of $65.60 in cash plus a contingent value right (CVR) worth up to $20.65 per share.
- This deal follows an earlier offer by Pfizer of roughly $7.3 billion in September before Novo Nordisk’s competing bid
- The deal is expected to close following Metsera’s shareholder meeting scheduled for 13 November.
Why the rivalry heated up
Novo Nordisk entered the fray with a competing unsolicited bid, triggering a sharp jump in Metsera’s share price — which climbed around 60 % since Novo’s intervention.
Metsera’s board cited a letter from the U.S. Federal Trade Commission (FTC) to Metsera and Novo, warning about significant antitrust risks from the transaction with Novo. That tipped the balance in favour of Pfizer’s offer.
Analysts described the bidding spat as akin to a “Game of Thrones”-style fight for control of a highly coveted biotech asset.
Strategic implications & outlook
For Pfizer, the acquisition is a clear signal of its ambition to crack the obesity-treatment market, which some analysts estimate might reach up to $150 billion in coming years
Yet the investment comes with risks: Metsera’s lead assets — injectable GLP-1 treatment MET-097i and pancreatic hormone amylin analogue MET-233i — are still in development, and estimates suggest a combined peak sales around $5 billion
As one analyst noted, the deal rests on ambitious projections and generous assumptions about pricing and uptake of obesity drugs.
For Novo Nordisk, stepping away from the race signals confidence in its existing pipeline while freeing up capital to pursue other strategic acquisitions. Membership in the obesity-drug competition remains fierce, with Eli Lilly also making major advances
What to watch
- Regulatory review and antitrust clearance: given the scrutiny that hampered Novo’s bid, Pfizer’s deal will likely draw similar attention.
- Progress in Metsera’s clinical trials and time to market: the faster the development and approval, the quicker Pfizer can begin to recover its investment.
- Competitive dynamics: how rivals like Lilly and Novo respond in terms of new drugs, pricing, and acquisitions.
- Market reaction: investors will weigh the optimism of pipeline projections versus the risk inherent in early-stage assets.
Conclusion:
Pfizer’s acquisition of Metsera marks a bold move into the obesity-treatment arena, pushing the pharma giant ahead of a rival in a high-stakes market. The deal carries significant upside, but also meaningful developmental and regulatory risks. How Pfizer executes post-close will determine whether the price paid proves justified.
Let me know if you’d like a deeper dive into Metsera’s pipeline, a comparison of our key players’ obesity-drug strategies, or an infographic for the acquisition timeline.
